Understanding how a protein called SHIP1 works in human immune cells
Deciphering the mechanism of SHIP1 regulation in human neutrophils
This research explores how human immune cells, specifically neutrophils, respond to signals in the body by studying a key protein called SHIP1.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oregon NIH-funded |
| Lab location | 1 site (Eugene, United States) |
| Project ID | NIH-11373379 on NIH RePORTER |
What this research studies
Our immune cells, like neutrophils, constantly interpret chemical messages to decide how to act, such as moving towards an infection. This project aims to understand the complex communication between different signaling molecules within these cells, focusing on how a lipid phosphatase called SHIP1 helps control these responses. We are looking at how SHIP1 interacts with other molecules at the cell's surface and how it triggers a unique 'traveling wave' of signals. By using advanced techniques, we hope to uncover how SHIP1 is activated and how it influences the cell's ability to react to its environment.
Who could benefit from this research
Good fit: This foundational research is relevant to anyone interested in how their immune system works, particularly those with conditions involving neutrophil function or immune cell signaling.
Not a fit: Patients will not receive direct medical benefit from participating in this basic science research, as it focuses on fundamental biological mechanisms.
Why it matters
Potential benefit: A deeper understanding of SHIP1's role in immune cell behavior could lead to new ways to treat conditions where immune responses are overactive or not strong enough.
How similar studies have performed: This project builds on existing knowledge of immune cell signaling, but it explores novel aspects of SHIP1's role and a unique 'excitable' signaling behavior within human neutrophils.
Where this research is happening
Eugene, United States
- University of Oregon — Eugene, United States (Active)
Researchers
- Principal investigator: Hansen, Scott David — University of Oregon
- Study coordinator: Hansen, Scott David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.